Imetelstat clinical trials
Also written GRN163L.
How each study uses imetelstat is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the imetelstat studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 6 Jun 2024 · RYTELO · NDA 217779 (FDA, Drugs@FDA)
- European Union
- 7 Mar 2025 · Rytelo · EMEA/H/C/006105 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
23 studies that test it; most in 2010 (3); 2 more planned to start later
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 2 |
| 2008 | 2 |
| 2010 | 3 |
| 2011 | 2 |
| 2012 | 2 |
| 2013 | 2 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 15 · Other 10
Geron Corporation (14) · Children's Oncology Group (3) · GCP-Service International West GmbH (1) · Indiana University (1) · M.D. Anderson Cancer Center (1) · University of Wisconsin, Madison (1) · Douglas Tremblay (1) · Pediatric Brain Tumor Consortium (1)
Often tested with
Tested in the same studies.
Ruxolitinib (1) · Cytarabine (1) · Fludarabine (1) · Azacitidine (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test imetelstat.
- Feb 2027A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With MyelofibrosisPhase 1 · Geron Corporation
- May 2027Phase 2 Study Of Imetelstat for Patient With Myelodysplastic/Myeloproliferative NeoplasmsPhase 2 · M.D. Anderson Cancer Center
Studies
Open first, then newest update. How each study uses imetelstat is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 25
- Phase 2 Study Of Imetelstat for Patient With Myelodysplastic/Myeloproliferative NeoplasmsNot yet recruitingPhase 2M.D. Anderson Cancer CenterNCT07549451Written as Imetelstat
- Maintenance Treatment With Imetelstat in Patients With High-Risk Myeloid Neoplasms After Allo-SCTNot yet recruitingPhase 1University of Wisconsin, MadisonNCT07909733Written as imetelstat
- A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to TherapyRecruitingPhase 1Children's Oncology GroupNCT06247787Written as Imetelstat
- Imetelstat Combinations in Relapsed AMLRecruitingPhase 1Douglas TremblayNCT07320235Written as Imetelstat
- Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based TherapyCompletedPhase 2GCP-Service International West GmbHNCT05583552Written as Imetelstat sodium
- A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With MyelofibrosisActive, not recruitingPhase 1Geron CorporationNCT05371964Written as Imetelstat sodium
- Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)Active, not recruitingPhase 2/3Geron CorporationNCT02598661Written as Imetelstat Sodium
- A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor TreatmentActive, not recruitingPhase 3Geron CorporationNCT04576156Written as Imetelstat
- Open Label Study With Imetelstat to Determine Effect of Imetelstat in Patients w/ Previously Treated Multiple MyelomaCompletedPhase 2Geron CorporationNCT01242930Written as Imetelstat (7.5 mg/kg)
- Imetelstat Sodium in Treating Participants With Primary or Secondary MyelofibrosisCompletedPhase 2Geron CorporationNCT01731951Written as Imetelstat
- Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) InhibitorCompletedPhase 2Geron CorporationNCT02426086Written as Imetelstat 4.7 mg/kg
- Imetelstat Given Intravenously Alone and With Standard 13-Cis-Retinoic Acid in Children With NeuroblastomaWithdrawnPhase 1NCIC Clinical Trials GroupNCT01916187Written as Imetelstat
- Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid TumorsWithdrawnPhase 2Children's Oncology GroupNCT02011126Written as Imetelstat Sodium
- Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain TumorsTerminatedPhase 2Pediatric Brain Tumor ConsortiumNCT01836549Written as imetelstat sodium
- Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia VeraCompletedPhase 2Geron CorporationNCT01243073Written as Imetelstat
- Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy in Non-small Cell Lung Cancer (NSCLC)CompletedPhase 2Geron CorporationNCT01137968Written as imetelstat
- Safety and Dose Study of GRN163L to Treat Patients With Chronic Lymphoproliferative Disease(CLD)CompletedPhase 1Geron CorporationNCT00124189Written as GRN163L
- Safety and Dose Study of GRN163L and Velcade to Treat Patients With Refractory or Relapsed MyelomaCompletedPhase 1Geron CorporationNCT00718601Written as Imetelstat Sodium (GRN163L)
- Safety and Dose Study of GRN163L Administered to Treat Patients With Refractory or Relapsed Multiple MyelomaCompletedPhase 1Geron CorporationNCT00594126Written as Imetelstat Sodium (GRN163L)
- Safety and Dose Study of GRN163L Administered to Patients With Refractory or Relapsed Solid Tumor MalignanciesCompletedPhase 1Geron CorporationNCT00310895Written as Imetelstat Sodium (GRN163L)
See all 25 studies that test imetelstat →
Given beside what is tested · 1 — imetelstat is usual care or a partner of the new treatment
What changed recently
From the registry's own updates since Oct 17, 2026.
Newly registered1
Codes
What other systems call imetelstat · ClinicalTrials.gg INT005080
- MeSH (NLM) C519562imetelstatConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) F60NE4XB53IMETELSTATConfirmed FDA, NLM, Wikidata
- Wikidata Q21083935imetelstatConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C49084ImetelstatOne source FDA
- DrugBank DB14909One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C519562 | imetelstat | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | F60NE4XB53 | IMETELSTAT | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q21083935 | imetelstat | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C49084 | Imetelstat | One source FDA |
| DrugBank | DB14909 | — | One source Wikidata |
Also registered as imetelstat sodium (UNII 2AW48LAZ4I).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.